C. Serrano

发表

RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas

César Serrano, Joan Carles, J. Carles, 2016, Cancer.

Acute aortic dissection during sorafenib-containing therapy.

J. Carles, C. Serrano, C. Suarez, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours

J. Carles, S. Ramón y. Cajal, C. Serrano, 2013, Histopathology.

Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors

P. Hrelia, C. Serrano, S. Angelini, 2019, Therapeutic Advances in Medical Oncology.

Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

J. Fletcher, J. Carles, P. Nuciforo, 2020, Molecular Cancer Therapeutics.

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

J. Carles, J. Bellmunt, C. Serrano, 2012, European journal of cancer.

Emerging therapies for urothelial cancer.

J. Carles, C. Serrano, C. Valverde, 2012, Cancer treatment reviews.

The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.

R. DeMatteo, C. Serrano, I. Schaefer, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

C. Paweletz, V. Velculescu, J. Fletcher, 2019, Clinical Cancer Research.

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy

O. Mir, W. Tap, P. Rutkowski, 2021, The oncologist.

Acute lung injury associated with docetaxel and bevacizumab.

C. Serrano, J. Cortés, M. Montero, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Hyperprogressive disease in patients with metastatic genitourinary tumors treated with immune checkpoint inhibitors.

J. Carles, C. Serrano, C. Valverde, 2019, Journal of Clinical Oncology.

BRAF and KRAS mutations in penile cancer and their correlation with clinical features.

J. Carles, C. Serrano, J. Hernández-Losa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

J. Fletcher, T. Clackson, M. Heinrich, 2014, Clinical Cancer Research.

Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options

S. Turroni, P. Hrelia, C. Serrano, 2022, Cancer science.

Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy

J. Ramón‐Azcón, J. Montero, C. Serrano, 2022, npj Precision Oncology.

miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs

P. Hrelia, C. Serrano, S. Angelini, 2022, International journal of molecular sciences.

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Robin L. Jones, J. Blay, M. Heinrich, 2022, BMC cancer.

Cancer as a Paradigm for Translational and Clinical Biomedical Research

G. Demetri, C. Serrano, 2017 .

Angiosarcoma of the ovary: is it always a lethal disease?

I. Braña, C. Serrano, A. Oaknin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soft Tissue and Uterine Leiomyosarcoma.

S. George, I. Ray-Coquard, C. Serrano, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GEIS guidelines for gastrointestinal sarcomas (GIST).

J. Martín-Broto, C. Serrano, C. Valverde, 2017, Cancer treatment reviews.

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Robin L. Jones, J. Blay, M. Heinrich, 2020, The Lancet. Oncology.

Recent advances in the treatment of gastrointestinal stromal tumors

S. George, C. Serrano, 2014, Therapeutic advances in medical oncology.

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

C. Antonescu, J. Desai, J. Fletcher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

J. Fletcher, J. Carles, S. George, 2020, BMC Cancer.

The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth

C. Serrano, E. Serrano-Candelas, M. Guerrero, 2022, Cancer Gene Therapy.

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth

D. Arango, J. Arribas, C. Serrano, 2018, Molecular oncology.

Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma

G. Demetri, M. Muto, S. George, 2014, Cancer.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

M. Bertagnolli, J. Fletcher, G. Demetri, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors

C. Serrano, S. Bauer, 2022, Current Oncology Reports.

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

J. Fletcher, J. Carles, S. George, 2020, BMC Cancer.

Hormone dependency in metastatic low-grade leiomyosarcoma following uterine smooth muscle tumour of uncertain malignant potential

S. Tirumani, C. Raut, M. Nucci, 2014, BMJ Case Reports.

New treatments in advanced gastrointestinal stromal tumor

C. Serrano, 2021, Current opinion in oncology.

Gastrointestinal stromal tumors (GISTs): SEAP–SEOM consensus on pathologic and molecular diagnosis

J. Martín-Broto, C. Serrano, J. López-Guerrero, 2017, Clinical and Translational Oncology.

Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time?

C. Serrano, Alfonso García-Valverde, Daniel F. Pilco-Janeta, 2021, Current Treatment Options in Oncology.

Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy

J. Tabernero, B. Markman, C. Serrano, 2010, Cancer journal.

Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade

S. George, C. Serrano, 2020, Clinical Cancer Research.

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

Robin L. Jones, O. Mir, W. Tap, 2021, European journal of cancer.

Emerging drugs for the treatment of gastrointestinal stromal tumors

C. Serrano, Alfonso García-Valverde, Daniel F. Pilco-Janeta, 2021, Expert opinion on emerging drugs.

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward

C. Serrano, C. Valverde, D. García-Illescas, 2021, Therapeutic advances in medical oncology.

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.

Robin L. Jones, O. Mir, W. Tap, 2020, The Lancet. Oncology.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

J. Carles, S. George, C. Serrano, 2017, Targeted Oncology.

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)

J. Martín-Broto, C. Serrano, A. Poveda, 2016, Clinical and Translational Oncology.

Acute severe hypothyroidism induced by sunitinib.

A. Prat, C. Serrano, C. Valverde, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

Robin L. Jones, J. Blay, M. Heinrich, 2021, The oncologist.

Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis

C. Serrano, Anu Gupta, Jarnail Singh, 2021, Molecular Cancer Therapeutics.

Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC)

E. Felip, P. Martínez, C. Serrano, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor

M. Gut, J. Barretina, J. Fletcher, 2021, Oncogene.

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.

J. Carles, J. Arribas, S. Landolfi, 2018, The oncologist.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients

J. Martín-Broto, C. Serrano, J. López-Guerrero, 2018, Oncotarget.

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy

C. Serrano, Miguel Henriques-Abreu, 2021, Expert review of anticancer therapy.

Toxicity analysis of adjuvant radiotherapy in breast cancer

C. Serrano, M. Calvo, M. A. Ariza, 2013 .

The rs17084733 variant in the KIT 3’ UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility

F. Ferrè, P. Hrelia, C. Serrano, 2019, Epigenetics.

J. Baselga, J. Tabernero, S. Cosimo, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib

P. Boisguérin, C. Serrano, Sébastien Deshayes, 2023, International journal of molecular sciences.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

J. Martín-Broto, C. Serrano, V. Martínez-Marín, 2023, Clinical and Translational Oncology.

Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).

Robin L. Jones, O. Mir, W. Tap, 2019, Journal of Clinical Oncology.

A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.

C. Serrano, C. Romagosa, C. Valverde, 2021 .

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

Robin L. Jones, R. Riedel, Yoon-Koo Kang, 2020, The oncologist.

Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database

C. Serrano, R. Pestana, 2023, Frontiers in Oncology.

INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

M. Heinrich, S. George, J. Zalcberg, 2019, Annals of Oncology.

Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.

W. Ou, C. Serrano, Xiaoyan Wang, 2023, Biochimica et biophysica acta. Molecular basis of disease.

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Robin L. Jones, J. Blay, M. Heinrich, 2021, Clinical Cancer Research.

O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

J. Blay, M. Heinrich, S. George, 2020 .

1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

A. Italiano, B. Vincenzi, C. Serrano, 2021, Annals of Oncology.

Steady diet as prophylaxis of acute diarrhea in preoperative pelvic radiotherapy of rectal adenocarcinoma

C. Serrano, S. G. Cabezas, A. P. Eito, 2013 .

PD-0277 STEADY DIET AS PROPHYLAXIS OF ACUTE DIARRHEA IN PREOPERATIVE PELVIC RADIOTHERAPY OF RECTAL ADENOCARCINOMA

C. Serrano, S. G. Cabezas, A. Luque, 2012 .

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.

P. Hrelia, C. Serrano, S. Angelini, 2023, Pharmacology & therapeutics.

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

M. Heinrich, J. Zalcberg, M. Mehren, 2021, Annals of Oncology.

4005 Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors?

J. Baselga, S. Cosimo, C. Serrano, 2009 .

Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).

C. Paweletz, V. Velculescu, J. Fletcher, 2018 .

The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth

C. Serrano, E. Serrano-Candelas, M. Guerrero, 2022, Cancer Gene Therapy.

Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.

J. Carles, C. Serrano, C. Valverde, 2019, Journal of Clinical Oncology.

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours

J. Carles, S. Ramón y. Cajal, C. Serrano, 2013, Histopathology.

2023 GEIS Guidelines for gastrointestinal stromal tumors

J. Martín-Broto, C. Serrano, J. López-Guerrero, 2023, Therapeutic advances in medical oncology.

Soft Tissue and Uterine Leiomyosarcoma.

S. George, I. Ray-Coquard, C. Serrano, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

J. Blay, A. Italiano, J. Martín-Broto, 2023, Molecular Cancer.

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2023, European Journal of Cancer.

Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.

Robin L. Jones, M. Heinrich, S. George, 2023, Journal of Clinical Oncology.

INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.

Robin L. Jones, J. Blay, M. Heinrich, 2023, Journal of Clinical Oncology.

Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.

Robin L. Jones, W. Tap, M. Heinrich, 2023, Journal of Clinical Oncology.

Angiosarcoma of the ovary: is it always a lethal disease?

I. Braña, C. Serrano, A. Oaknin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.